Genakumab
- Generic Name
- Genakumab
A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain
- Conditions
- Endometriosis-related Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT06963177
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
- Conditions
- Systemic Sclerosis Associated Interstitial Lung DiseaseRheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- Interventions
- Drug: GenSci048 placebo
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06189495
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
Safety & Efffficacy of Genakumab in Patients With Frequent Flares
- Conditions
- Acute Gout Arthritis
- Interventions
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 313
- Registration Number
- NCT05983445
- Locations
- 🇨🇳
Fudan University Affiliated Huashan Hospital, Shanghai, Shanghai, China
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
- Conditions
- Active Systemic Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05925452
- Locations
- 🇨🇳
Children's Hospital Affiliated to Capital Medical University, Beijing, Benjing, China
🇨🇳Children's Hospital Affiliated to Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Hunan Children's Hospital, Changsha, Hunan, China
Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults
- Conditions
- Interstitial Lung Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05894148
- Locations
- 🇨🇳
Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, Sichuan, China
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05441046
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: Placebo for this trial
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04337437
- Locations
- 🇨🇳
Clinical Pharmacology Research Center of Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.